BioAge Labs (NASDAQ:BIOA) Shares Gap Up – Should You Buy?

BioAge Labs, Inc. (NASDAQ:BIOA) gapped up prior to trading on Friday . The stock had previously closed at $16.25, but opened at $16.90. BioAge Labs shares last traded at $16.40, with a volume of 70,644 shares changing hands.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Oppenheimer started coverage on shares of BioAge Labs in a report on Wednesday, February 25th. They set an “outperform” rating and a $60.00 target price for the company. Wall Street Zen upgraded shares of BioAge Labs from a “sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, January 27th. Needham & Company LLC started coverage on shares of BioAge Labs in a research note on Friday. They set a “buy” rating and a $50.00 price objective for the company. Finally, Morgan Stanley set a $23.00 price objective on BioAge Labs in a report on Wednesday, February 4th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, BioAge Labs has a consensus rating of “Moderate Buy” and a consensus price target of $46.25.

BioAge Labs Stock Performance

The firm has a fifty day moving average price of $19.88 and a 200 day moving average price of $13.02. The company has a market cap of $716.74 million, a price-to-earnings ratio of -7.21 and a beta of 1.22.

BioAge Labs (NASDAQ:BIOA) last issued its earnings results on Tuesday, March 24th. The company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.11. The business had revenue of $3.08 million for the quarter. BioAge Labs had a negative net margin of 896.11% and a negative return on equity of 27.86%.

Insider Activity

In related news, CEO Kristen Fortney sold 233,107 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $18.12, for a total value of $4,223,898.84. Following the completion of the sale, the chief executive officer directly owned 976,949 shares in the company, valued at approximately $17,702,315.88. This trade represents a 19.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Dov A. Md Goldstein sold 27,000 shares of BioAge Labs stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $19.70, for a total value of $531,900.00. Following the transaction, the chief financial officer owned 22,408 shares of the company’s stock, valued at $441,437.60. The trade was a 54.65% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 267,540 shares of company stock valued at $4,895,168. 20.82% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. acquired a new position in shares of BioAge Labs during the 4th quarter worth approximately $13,892,000. Janus Henderson Group PLC acquired a new stake in BioAge Labs during the 4th quarter valued at $5,406,000. Millennium Management LLC boosted its position in BioAge Labs by 749.8% during the third quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock worth $1,803,000 after purchasing an additional 270,479 shares during the period. Sphera Funds Management LTD. acquired a new position in shares of BioAge Labs in the fourth quarter valued at $3,215,000. Finally, Invesco Ltd. acquired a new position in shares of BioAge Labs in the fourth quarter valued at $3,025,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.